Funding New Treatments
TB Alliance makes every effort to ensure that donor money is put to effective use and contributes directly to the development of impactful new TB drug regimens that are adopted, available and affordable.
Bridging the Funding Gap
In its 2017 report on tuberculosis research funding trends, the Treatment Action Group estimated that the world spent a total of $256.6 million on research and development for TB drugs in 2016.
This investment has enabled the development of a robust pipeline of drug candidates and drug regimens that are positioned to make an impact on the global TB landscape. However, today's funding realities represent a dramatic shortfall in comparison to the five-year funding target of more than $4.1 billion set forth in the Stop TB Partnership's Global Plan to End TB, 2016–2020.